Patients with high SNORA28/LIFR expression had shorter overall survival (OS) and recurrence‐free survival (RFS) compared to those without high expression, suggesting that LIFR functions as an oncogene in CRC and that the SNORA28/LIFR pathway promotes CRC progression. Here, LIFR is linked to colorectal carcinoma.